{
  "id": 4235022,
  "title": "Monoclonal antibody targeting interleukin-6 achieves sustained reductions in inflammation biomarkers through six months",
  "url": "https://urgent.news/2026/08/29/monoclonal-antibody-targeting-interleukin-6-achieves-sustained",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-29T16:33:55.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-08-monoclonal-antibody-interleukin-sustained-reductions.html"
  },
  "original_language": "en",
  "account": null,
  "summary": "An investigational monoclonal antibody, pacibekitug, has shown sustained reductions in inflammation-related biomarkers through six months in patients with chronic kidney disease and elevated inflammatory risk associated with heart disease, according to a phase 2 clinical trial called TRANQUILITY. The study, presented at the European Society of Cardiology Congress, found that pacibekitug produced time-averaged reductions in high-sensitivity C-reactive protein (hsCRP) ranging from 76% to 89% compared to a 7% increase in the placebo group. The long-acting monoclonal antibody targets the interleukin-6 (IL-6) pathway, a signaling protein involved in inflammatory processes associated with cardiovascular risk. The next step is to determine if these biomarker effects translate into improved cardiovascular outcomes in larger studies.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}